Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use

被引：11
|
作者：
Ahmadzadehfar, Hojjat [1 ]
Essler, Markus [1 ]
Schaefers, Michael [2 ]
Rahbar, Kambiz [2 ]
机构：
[1] Univ Hosp Bonn, Dept Nucl Med, Sigmund Freud Str 25, D-53127 Bonn, Germany
[2] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2016年 / 43卷 / 12期
关键词：
D O I：
10.1016/j.nucmedbio.2016.08.003
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：835 / 835
页数：1
相关论文
共 50 条
  • [31] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Braeuer, Axel
    Grubert, Lena Sophie
    Roll, Wolfgang
    Schrader, Andres Jan
    Schaefers, Michael
    Boegemann, Martin
    Rahbar, Kambiz
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1663 - 1670
  • [32] German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Haberkorn, Uwe
    Schaefers, Michael
    Essler, Markus
    Baum, Richard P.
    Kulkarni, Harshad R.
    Schmidt, Matthias
    Drzezga, Alexander
    Bartenstein, Peter
    Pfestroff, Andreas
    Luster, Markus
    Luetzen, Ulf
    Marx, Marlies
    Prasad, Vikas
    Brenner, Winfried
    Heinzel, Alexander
    Mottaghy, Felix M.
    Ruf, Juri
    Meyer, Philipp Tobias
    Heuschkel, Martin
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang Peter
    Krause, Bernd Joachim
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 : 257S - 262S
  • [33] Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
    Filss, Christian
    Heinzel, Alexander
    Mueller, Berthold
    Vogg, Andreas T. J.
    Langen, Karl-Josef
    Mottaghy, Felix M.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (01): : 19 - 25
  • [34] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Axel Bräuer
    Lena Sophie Grubert
    Wolfgang Roll
    Andres Jan Schrader
    Michael Schäfers
    Martin Bögemann
    Kambiz Rahbar
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1663 - 1670
  • [35] Radioligand Therapy of metastatic Prostate Cancer with Lu-PSMA-617
    Manych, Matthias
    [J]. AKTUELLE UROLOGIE, 2017, 48 (05)
  • [36] Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer
    Satapathy, Swayamjeet
    Das, Chandan Krushna
    Parihar, Ashwin Singh
    Sood, Ashwani
    Mittal, Bhagwant R.
    [J]. CLINICAL NUCLEAR MEDICINE, 2021, 46 (07) : 582 - 583
  • [37] Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride
    Ahmadzadehfar, Hojjat
    Zimbelmann, Stefanie
    Yordanova, Anna
    Fimmers, Rolf
    Kuerpig, Stefan
    Eppard, Elisabeth
    Gaertner, Florian C.
    Wei, Xiao
    Hauser, Stefan
    Essler, Markus
    [J]. ONCOTARGET, 2017, 8 (33) : 55567 - 55574
  • [38] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [39] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [40] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    [J]. AKTUELLE UROLOGIE, 2022, 53 (02)
12345